Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.006 AUD | +20.00% | 0.00% | +20.00% |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Sales 2022 | 3.29M 2.17M | Sales 2023 | 4.1M 2.7M | Capitalization | 25.69M 16.91M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.32M | Net income 2023 | -1M -658K | EV / Sales 2022 | 15 x |
Net cash position 2022 | 8.47M 5.58M | Net cash position 2023 | 4.08M 2.69M | EV / Sales 2023 | 5.26 x |
P/E ratio 2022 |
-22.6
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.95% |
1 day | +20.00% | ||
Current month | +20.00% | ||
1 month | +9.09% | ||
3 months | +50.00% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 20-07-12 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-10-21 | |
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Alan Yamashita
BRD | Director/Board Member | 74 | 19-02-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.006 | +20.00% | 2 654 000 |
24-05-08 | 0.005 | 0.00% | 8,872,394 |
24-05-07 | 0.005 | -16.67% | 107,127 |
24-05-06 | 0.006 | +20.00% | 1,811,339 |
24-05-03 | 0.005 | -16.67% | 3,056,860 |
Delayed Quote Australian S.E., May 08, 2024 at 11:13 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+20.00% | 21.24M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- IVX Stock